Filip Y. De Vos

University Medical Center Utrecht, Cancer Center, Department of Medical Oncology

Disclosure: NO DISCLOSURE DATA

Presentation(s):

• ACTR-30 - Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG)

  Friday, November 22
  3:25 PM – 3:35 PM

• NCOG-08 - Cognitive deficits as a predictor of the course of treatment in diffuse glioma

  Friday, November 22
  8:26 PM – 8:30 PM

• ACTR-21 - A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in Epidermal Growth Factor Receptor (EGFR) amplified (amp) newly diagnosed glioblastoma (nGBM)

  Saturday, November 23
  11:50 AM – 12:00 PM

• NCMP-15 - Bevacizumab for the treatment of cerebral radiation necrosis: a retrospective cohort study

  Saturday, November 23
  5:00 PM – 7:00 PM

• ACTR-33 - Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

  Saturday, November 23
  5:00 PM – 7:00 PM